Xtant Medical Holdings, Inc.XTNTNYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank67
5Y CAGR-27.2%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-27.2%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 12.01% |
| Q2 2025 | 27.77% |
| Q1 2025 | -15.13% |
| Q4 2024 | -25.53% |
| Q3 2024 | 10.22% |
| Q2 2024 | 20.68% |
| Q1 2024 | 7.11% |
| Q4 2023 | 0.41% |
| Q3 2023 | 172.22% |
| Q2 2023 | 3.45% |
| Q1 2023 | -25.00% |
| Q4 2022 | 1.31% |
| Q3 2022 | -4.98% |
| Q2 2022 | 13.15% |
| Q1 2022 | 41.06% |
| Q4 2021 | -42.37% |
| Q3 2021 | 7.82% |
| Q2 2021 | 13.55% |
| Q1 2021 | 67.19% |
| Q4 2020 | -27.27% |
| Q3 2020 | 58.56% |
| Q2 2020 | -54.69% |
| Q1 2020 | -4.67% |
| Q4 2019 | 26.60% |
| Q3 2019 | -3.33% |
| Q2 2019 | -19.85% |
| Q1 2019 | -49.90% |
| Q4 2018 | 50.72% |
| Q3 2018 | -16.99% |
| Q2 2018 | 0.97% |
| Q1 2018 | -30.79% |
| Q4 2017 | 18.63% |
| Q3 2017 | -21.22% |
| Q2 2017 | -8.39% |
| Q1 2017 | -12.47% |
| Q4 2016 | -14.07% |
| Q3 2016 | 18.50% |
| Q2 2016 | -12.86% |
| Q1 2016 | -12.42% |
| Q4 2015 | 29.29% |